Scientific Opinion on the substantiation of health claims related to konjac mannan (glucomannan) and reduction of body weight (ID 854, 1556, 3725), reduction of post-prandial glycaemic responses (ID 1559), maintenance of normal blood glucose concentrations (ID 835, 3724), maintenance of normal (fasting) blood concentrations of triglycerides (ID 3217), maintenance of normal blood cholesterol concentrations (ID 3100, 3217), maintenance of normal bowel function (ID 834, 1557, 3901) and decreasing potentially pathogenic gastro-intestinal microorganisms (ID 1558) pursuant to Article 13(1) of Regulation (EC) No 1924/2006
konjac mannan, glucomannan, glycaemic control, weight management, body weight, blood lipids, blood glucose, bowel function, intestinal transit, potentially pathogenic organisms, health claims
First published in the EFSA Journal:
19 October 2010
Adopted:
10 September 2010
Last Updated:
9 December 2010. This version replaces the previous one/s.
Type:
Scientific Opinion
Read it on the Wiley Online Library: Abstract
No abstract available
© European Food Safety Authority, 2010
Panel members at the time of adoption
Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Hannu Korhonen, Pagona Lagiou, Martinus Løvik, Rosangela Marchelli, Ambroise Martin, Bevan Moseley, Monika Neuhäuser-Berthold, Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, Sean (J.J.) Strain, Stephan Strobel, Inge Tetens, Daniel Tomé, Hendrik van Loveren and Hans Verhagen.
Panel on Dietetic Products, Nutrition and Allergies
Contact:
nda [at] efsa.europa.eu
doi:
10.2903/j.efsa.2010.1798
EFSA Journal 2010;8(10):1798
Question Number:
On request from:
European Commission